Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. / Samocha-Bonet, Dorit; Chisholm, Donald J; Gribble, Fiona M; Coster, Adelle C F; Carpenter, Kevin H; Jones, Graham R D; Holst, Jens Juul; Greenfield, Jerry R.

In: PloS one, Vol. 9, No. 11, e113366, 2014, p. 1-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Samocha-Bonet, D, Chisholm, DJ, Gribble, FM, Coster, ACF, Carpenter, KH, Jones, GRD, Holst, JJ & Greenfield, JR 2014, 'Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study', PloS one, vol. 9, no. 11, e113366, pp. 1-7. https://doi.org/10.1371/journal.pone.0113366

APA

Samocha-Bonet, D., Chisholm, D. J., Gribble, F. M., Coster, A. C. F., Carpenter, K. H., Jones, G. R. D., Holst, J. J., & Greenfield, J. R. (2014). Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. PloS one, 9(11), 1-7. [e113366]. https://doi.org/10.1371/journal.pone.0113366

Vancouver

Samocha-Bonet D, Chisholm DJ, Gribble FM, Coster ACF, Carpenter KH, Jones GRD et al. Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. PloS one. 2014;9(11):1-7. e113366. https://doi.org/10.1371/journal.pone.0113366

Author

Samocha-Bonet, Dorit ; Chisholm, Donald J ; Gribble, Fiona M ; Coster, Adelle C F ; Carpenter, Kevin H ; Jones, Graham R D ; Holst, Jens Juul ; Greenfield, Jerry R. / Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. In: PloS one. 2014 ; Vol. 9, No. 11. pp. 1-7.

Bibtex

@article{b25ae4c10fd64ca4be2a4c98349308f1,
title = "Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study",
abstract = "BACKGROUND AND AIMS: L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.METHODS: Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c) 7.1±0.3% (54±4 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4 weeks in a randomized crossover study.RESULTS: HbA1c (P = 0.007) and fructosamine (P = 0.02) decreased modestly, without significant time-treatment interactions (both P = 0.4). Blood urea increased (P<0.001) without a significant time-treatment interaction (P = 0.8), but creatinine and estimated glomerular filtration rate (eGFR) were unchanged (P≥0.5). Red blood cells, hemoglobin, hematocrit, and albumin modestly decreased (P≤0.02), without significant time-treatment interactions (P≥0.4). Body weight and plasma electrolytes remained unchanged (P≥0.2).CONCLUSIONS: Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.TRIAL REGISTRATION: ClincalTrials.gov NCT00673894.",
author = "Dorit Samocha-Bonet and Chisholm, {Donald J} and Gribble, {Fiona M} and Coster, {Adelle C F} and Carpenter, {Kevin H} and Jones, {Graham R D} and Holst, {Jens Juul} and Greenfield, {Jerry R}",
year = "2014",
doi = "10.1371/journal.pone.0113366",
language = "English",
volume = "9",
pages = "1--7",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

RIS

TY - JOUR

T1 - Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study

AU - Samocha-Bonet, Dorit

AU - Chisholm, Donald J

AU - Gribble, Fiona M

AU - Coster, Adelle C F

AU - Carpenter, Kevin H

AU - Jones, Graham R D

AU - Holst, Jens Juul

AU - Greenfield, Jerry R

PY - 2014

Y1 - 2014

N2 - BACKGROUND AND AIMS: L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.METHODS: Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c) 7.1±0.3% (54±4 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4 weeks in a randomized crossover study.RESULTS: HbA1c (P = 0.007) and fructosamine (P = 0.02) decreased modestly, without significant time-treatment interactions (both P = 0.4). Blood urea increased (P<0.001) without a significant time-treatment interaction (P = 0.8), but creatinine and estimated glomerular filtration rate (eGFR) were unchanged (P≥0.5). Red blood cells, hemoglobin, hematocrit, and albumin modestly decreased (P≤0.02), without significant time-treatment interactions (P≥0.4). Body weight and plasma electrolytes remained unchanged (P≥0.2).CONCLUSIONS: Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.TRIAL REGISTRATION: ClincalTrials.gov NCT00673894.

AB - BACKGROUND AND AIMS: L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.METHODS: Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c) 7.1±0.3% (54±4 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4 weeks in a randomized crossover study.RESULTS: HbA1c (P = 0.007) and fructosamine (P = 0.02) decreased modestly, without significant time-treatment interactions (both P = 0.4). Blood urea increased (P<0.001) without a significant time-treatment interaction (P = 0.8), but creatinine and estimated glomerular filtration rate (eGFR) were unchanged (P≥0.5). Red blood cells, hemoglobin, hematocrit, and albumin modestly decreased (P≤0.02), without significant time-treatment interactions (P≥0.4). Body weight and plasma electrolytes remained unchanged (P≥0.2).CONCLUSIONS: Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.TRIAL REGISTRATION: ClincalTrials.gov NCT00673894.

U2 - 10.1371/journal.pone.0113366

DO - 10.1371/journal.pone.0113366

M3 - Journal article

C2 - 25412338

VL - 9

SP - 1

EP - 7

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 11

M1 - e113366

ER -

ID: 132047058